Please assess the completion status of the following clinical trial:

Trial Title: Corneal Collagen Cross-linking for Progressive Keratoconus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of keratoconus~* Documented progression over previous 24 months~* Decreased BSCVA~* Must complete all study visits~Exclusion Criteria:~* Prior corneal surgery or Intacs~* History of delayed wound healing

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Corneal Collagen Cross-linking (CXL) Treatment Group (Type: ACTIVE_COMPARATOR): riboflavin ophthalmic solution and UVA irradiation
- Control Group (Type: SHAM_COMPARATOR): riboflavin ophthalmic solution without UVA irradiation.

Based on this trial design, predict the completion outcome and termination type (if applicable).